Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Onco-Innovations Ltd. ( (TSE:ONCO) ) has issued an announcement.
Onco-Innovations Limited has announced that its subsidiary, Inka Health, has received an Expression of Interest from AstraZeneca to join the PROmAI Consortium as a founding member. This consortium aims to advance AI methodologies in oncology by bringing together pharmaceutical companies and scientific experts to improve predictive modeling in cancer research. AstraZeneca’s involvement is seen as a validation of the initiative’s potential impact in oncology R&D, and the collaboration is expected to enhance trust and utility of AI-driven insights in drug development.
More about Onco-Innovations Ltd.
Onco-Innovations Limited is a Canadian company focused on cancer research and treatment, specializing in oncology. The company aims to prevent and treat cancer through pioneering research and innovative solutions. It holds an exclusive worldwide license for patented technology targeting solid tumors. Inka Health, a subsidiary of Onco-Innovations, is an AI-driven analytics company revolutionizing oncology research and drug development through advanced causal AI, using its proprietary platform, SynoGraph, to optimize treatment decisions and clinical trial design.
Average Trading Volume: 108,726
For an in-depth examination of ONCO stock, go to TipRanks’ Overview page.